Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma

Elotuzumab, an immunostimulatory monoclonal antibody targeting a signaling lymphocytic activation molecule F7 (SLAMF7), has been approved for patients with relapsed or refractory multiple myeloma (MM) in combination with lenalidomide, and dexamethasone. However, little is known regarding the use of elotuzumab for the treatment of immunoglobulin light chain amyloidosis with MM. We report the treatment of a patient with multiple relapsed MM and immunoglobulin light chain amyloidosis with ERD. This patient had a dramatic decrease in kappa free light chain and nephrotic range proteinuria after previous progressions on multiple lines of therapy. (C) 2018 Elsevier Inc. All rights reserved.